<DOC>
	<DOCNO>NCT02748707</DOCNO>
	<brief_summary>This phase II randomize clinical trial study effect COX-2 inhibitor Celecoxib EGFR tyrosine kinase inhibitor Erlotinib alone combination molecular marker apoptosis angiogenesis .</brief_summary>
	<brief_title>Effect COX-2 EGFR Suppression Molecular Markers Angiogenesis Proliferation Squamous Cell Carcinoma Oral Cavity - Prospective Randomized Study</brief_title>
	<detailed_description>Activation EGFR signal lead increase transcription COX-2 . Increased COX-2 transcription result enhance production PGs , include PGE2 , turn activate EGFR initiate positive feedback loop . Although majority HNSCC over-express EGFR , clinical response EGFR target agent modest . When mechanisms intrinsic resistance identify like mutation EGFR receptor , alternative therapeutic approach employ . In preclinical study , combine inhibitor COX-2 inhibitor EGFR tyrosine kinase effective either agent alone suppress tumor formation . Acquired resistance may amenable pharmacological intervention include deregulation EGFR degradation , constitutive activation overlap signal transduction pathway , especially cMET/HER3 , PI3K/Akt resistance pathway , angiogenesis epithelial mesenchymal transition . Preclinical data suggest COX-2 inhibitor affect describe acquired EGFR resistance pathway . We propose prospective phase II randomize trial base 2 X 2 factorial design patient randomize COX-2 inhibition vs. COX-2 inhibition . Each arm randomize erlotinib vs. erlotinib . This result follow treatment combination . Arm 1 : Celecoxib 200mg twice daily Arm 2 : Celecoxib 200mg twice daily + Erlotinib 150mg daily Arm 3 : Erlotinib 150mg alone Arm 4 : Control group drug Patients drug treatment arm receive prescribe drug 21 day tumor surgically resect . Having control group ethically justifiable average wait time hospital prior definitive treatment 30 day diagnosis . The study population consist patient resectable oral cavity squamous cell carcinoma see Tata memorial hospital . Tumor size estimate MRI Scans well clinical examination completion study drug .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Tongue Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . All patient squamous cell carcinoma oral cavity ( T2T4 , N12 , M0 ) candidate first line curative surgical treatment able swallow orally , preoperatively . 2 . Patients must least 18 year age . 3 . All patient must sign informed consent enrol study . 4 . Patients must able willing return clinic appropriately schedule interval . 5 . No use systemic steroid topical oral steroid preparation within three month . ( Topical nasal steroid spray cutaneous preparation minimal systemic absorption nasal dermatologic disorder allow ) . 6 . Premenopausal woman must use adequate birth control method negative pregnancy test prior entry . 7 . Karnofsky Performance Score 80 . 8 . The subject willing able fully participate duration study . 9 . If applicable , subject counsel smoking cessation . 10 . The subject meet follow laboratory eligibility criterion time exceed 4 week prior randomization . 11 . Hemoglobin level 10gm/dl , low limit normal . 12 . WBC count &gt; 3,000 mm3 . 13 . Platelets count &gt; 100,000 m3 . 14 . Total bilirubin , AST ( Aspartate Aminotransferase ) ALT ( Alanine transaminase ) ≤ 2 x ULN . 15 . Serum creatinine ≤ 2 x Upper limit Normal ( ULN ) 1 . History cardiovascular co morbidity 2 . Patients previous history head neck cancer 3 . Recent massive gastrointestinal hemorrhage 4 . An ongoing unmanaged serious infectious disease major metabolic disorder 5 . Neutrophil count &lt; 1 x 109 per liter platelet count &lt; 75 x 109 per liter study entry , 6 . Bilirubin &gt; 1.5fold upper limit normal , 7 . Kidney failure ( Glomerular filtration rate &lt; 40 mL/min ) . 8 . Pregnant woman 9 . Use nonsteroidal antiinflammatory drug ( NSAIDs ) corticosteroid within 2 week prior initial clinical evaluation 10 . The subject , opinion Institutional Principal Investigator , appropriate candidate study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>